secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001808665-25-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio Q1 net product sales $26.0M (-18% YoY), GAAP loss $13.5M; settles DOJ qui tam, transfers opioid liabilities
--------------------------------------------------------------------------------

- Net product sales $26.0M vs $31.9M YoY; GAAP net loss $13.5M ($0.14 loss per share) vs $4.5M loss.
- Adjusted EBITDA $0.2M vs $7.4M YoY; adjusted EPS ($0.04) vs $0.04 positive.
- Rolvedon net sales $13.1M (-10% YoY) on lower pricing; Indocin $5.5M (-37% YoY) on generic competition.
- Settled DOJ False Claims Act lawsuit and last Glumetza antitrust action; transferred subsidiary with opioid liabilities.
- Cash $87.3M; $40M in 6.5% convertible notes due 2027; no near-term maturities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866525000011/0001808665-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866525000011/asrt-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001808665-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer